Zylox-Tonbridge Acquires Optimed to Accelerate Global Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Should l Buy 02190?
Source: PRnewswire
- Global Expansion Milestone: Zylox-Tonbridge has entered into an acquisition agreement with Germany's Optimed, aiming to accelerate the global adoption of innovative vascular solutions by integrating R&D, manufacturing, and commercialization platforms, which is expected to significantly enhance market penetration.
- Operational Synergies: The acquisition will integrate the sales networks of both companies, leveraging Optimed's long-standing customer relationships in over 70 countries to improve product time-to-market and strengthen competitiveness in the European market.
- Efficient R&D Capabilities: Zylox-Tonbridge will fully unlock its R&D and manufacturing synergies in China and Germany, ensuring the provision of high-quality, reliable innovative medical solutions to meet evolving customer needs in global markets.
- Leadership Integration: Following the acquisition, Optimed's CEO Rüdiger Hausherr will continue to lead Optimed and report to Zylox-Tonbridge's Chairman Jonathon Zhong Zhao, ensuring strategic alignment and collaborative growth between the two companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy 02190?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on 02190
Wall Street analysts forecast 02190 stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.720
Low
Averages
High
Current: 23.720
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zylox-Tonbridge Acquires Optimed to Accelerate Global Expansion
- Global Expansion Milestone: Zylox-Tonbridge has entered into an acquisition agreement with Germany's Optimed, aiming to accelerate the global adoption of innovative vascular solutions by integrating R&D, manufacturing, and commercialization platforms, which is expected to significantly enhance market penetration.
- Operational Synergies: The acquisition will integrate the sales networks of both companies, leveraging Optimed's long-standing customer relationships in over 70 countries to improve product time-to-market and strengthen competitiveness in the European market.
- Efficient R&D Capabilities: Zylox-Tonbridge will fully unlock its R&D and manufacturing synergies in China and Germany, ensuring the provision of high-quality, reliable innovative medical solutions to meet evolving customer needs in global markets.
- Leadership Integration: Following the acquisition, Optimed's CEO Rüdiger Hausherr will continue to lead Optimed and report to Zylox-Tonbridge's Chairman Jonathon Zhong Zhao, ensuring strategic alignment and collaborative growth between the two companies.
See More
Zylox-Tonbridge Acquires Optimed to Accelerate Global Expansion
- Global Expansion Milestone: Zylox-Tonbridge's acquisition of Germany-based Optimed marks a significant milestone in its global expansion strategy, expected to enhance market entry efficiency by integrating R&D, manufacturing, and commercialization platforms.
- Operational Synergies: The acquisition is set to generate operational synergies by expanding the manufacturing base in Germany, ensuring a reliable supply of high-quality medical solutions while integrating both companies' sales networks to improve operational efficiency and reduce costs.
- Complementary Product Portfolios: Optimed's established sales network across over 70 countries and long-standing relationships with clinical experts will enable Zylox-Tonbridge to bring innovative products to market more rapidly, enhancing its competitiveness in the global market.
- Leadership Integration: Following the acquisition, Optimed's CEO Rüdiger Hausherr will continue to lead and report to Zylox-Tonbridge's CEO Jonathon Zhong Zhao, ensuring strategic alignment and collaborative development between the two companies.
See More
Zylox-Tonbridge Hosts Investor Open Day, Showcasing Global Competitiveness
- Investor Open Day: Zylox-Tonbridge hosted its Investor Open Day at the Zhuhai Innovation Center, welcoming nearly 150 institutional investors and sell-side analysts, showcasing its global competitiveness and innovation strategy aimed at enhancing market position through R&D-driven innovation and a global manufacturing platform.
- Product Innovation Showcase: The company highlighted its image-guided endovascular therapy platform, including the world's only real-time visualization-guided plaque removal solution, the ZYLOX Pantheris™, marking a significant advancement in precision intervention and elevating global medical standards.
- Accelerated Global Expansion: By the end of 2025, Zylox-Tonbridge established commercial coverage in 83 countries and regions and formed strategic partnerships with over 80 distributors and commercial partners, demonstrating the success of its globalization strategy and market penetration capabilities.
- Sustainable Growth Strategy: The CEO stated that by integrating innovation, industrialized manufacturing, and global commercialization, Zylox-Tonbridge is building a globally competitive vascular intervention platform, with cumulative product use expected to exceed one million procedures by 2025, reflecting strong physician adoption of its technologies.
See More
Zylox-Tonbridge Acquires Optimed to Accelerate Global Expansion
- Global Expansion Milestone: Zylox-Tonbridge has entered into an acquisition agreement with Germany's Optimed, aiming to accelerate the global adoption of innovative vascular solutions by integrating R&D, manufacturing, and commercialization platforms, which is expected to significantly enhance market penetration.
- Operational Synergies: The acquisition will integrate the sales networks of both companies, leveraging Optimed's long-standing customer relationships in over 70 countries to improve product time-to-market and strengthen competitiveness in the European market.
- Efficient R&D Capabilities: Zylox-Tonbridge will fully unlock its R&D and manufacturing synergies in China and Germany, ensuring the provision of high-quality, reliable innovative medical solutions to meet evolving customer needs in global markets.
- Leadership Integration: Following the acquisition, Optimed's CEO Rüdiger Hausherr will continue to lead Optimed and report to Zylox-Tonbridge's Chairman Jonathon Zhong Zhao, ensuring strategic alignment and collaborative growth between the two companies.
See More
Zylox-Tonbridge Acquires Optimed to Accelerate Global Expansion
- Global Expansion Milestone: Zylox-Tonbridge's acquisition of Germany-based Optimed marks a significant milestone in its global expansion strategy, expected to enhance market entry efficiency by integrating R&D, manufacturing, and commercialization platforms.
- Operational Synergies: The acquisition is set to generate operational synergies by expanding the manufacturing base in Germany, ensuring a reliable supply of high-quality medical solutions while integrating both companies' sales networks to improve operational efficiency and reduce costs.
- Complementary Product Portfolios: Optimed's established sales network across over 70 countries and long-standing relationships with clinical experts will enable Zylox-Tonbridge to bring innovative products to market more rapidly, enhancing its competitiveness in the global market.
- Leadership Integration: Following the acquisition, Optimed's CEO Rüdiger Hausherr will continue to lead and report to Zylox-Tonbridge's CEO Jonathon Zhong Zhao, ensuring strategic alignment and collaborative development between the two companies.
See More
Zylox-Tonbridge Hosts Investor Open Day, Showcasing Global Competitiveness
- Investor Open Day: Zylox-Tonbridge hosted its Investor Open Day at the Zhuhai Innovation Center, welcoming nearly 150 institutional investors and sell-side analysts, showcasing its global competitiveness and innovation strategy aimed at enhancing market position through R&D-driven innovation and a global manufacturing platform.
- Product Innovation Showcase: The company highlighted its image-guided endovascular therapy platform, including the world's only real-time visualization-guided plaque removal solution, the ZYLOX Pantheris™, marking a significant advancement in precision intervention and elevating global medical standards.
- Accelerated Global Expansion: By the end of 2025, Zylox-Tonbridge established commercial coverage in 83 countries and regions and formed strategic partnerships with over 80 distributors and commercial partners, demonstrating the success of its globalization strategy and market penetration capabilities.
- Sustainable Growth Strategy: The CEO stated that by integrating innovation, industrialized manufacturing, and global commercialization, Zylox-Tonbridge is building a globally competitive vascular intervention platform, with cumulative product use expected to exceed one million procedures by 2025, reflecting strong physician adoption of its technologies.
See More
